Navigation Links
Hospira Announces U.S. Approval of Generic Docetaxel
Date:3/9/2011

LAKE FOREST, Ill., March 9, 2011 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval of docetaxel. The medication is a generic version of Sanofi-Aventis's Taxotere®, and Hospira expects to launch the product later this month.

Hospira's docetaxel is approved for the treatment of a variety of cancers. In 2010, U.S. sales of Taxotere were approximately $1.2 billion.

Unlike original product formulations that require healthcare workers to take a two-step process prior to infusion, Hospira's docetaxel comes in a single-vial formulation that is designed to reduce the number of handling steps in the preparation of the product.

"Hospira's docetaxel will give U.S. cancer patients access to a high-quality, lower-cost alternative to the branded product, offers a differentiated delivery system designed to enhance caregiver safety, and reinforces Hospira's commitment to meet patient and caregiver needs in the oncology space," said Thomas Moore, president, U.S., Hospira.

Hospira will offer 20 mg, 80 mg and 160 mg vials of docetaxel at a 10 mg/mL concentration, the original concentration that customers have used safely for many years. Hospira already markets docetaxel in Europe and Australia.

Hospira's specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. In addition, many of its products are available in popular differentiated presentations, several of which are proprietary, such as ADD-Vantage™ drug delivery system and iSecure™ prefilled syringes. Therapeutic segments include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, emergency and other areas. Hospira also has robust pipelines of both generic and biosimilar drugs.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at www.hospira.com.

Private Securities Litigation Reform Act of 1995 --

A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the growth opportunities for generic specialty injectable products. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, legal, regulatory, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K filed with the Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira Board Names F. Michael Ball New CEO; Christopher B. Begley to Assume Executive Chairman Role
2. Hospira MedNet™ Portal Safety Software Benchmarking System Debuts at HIMSS
3. Hospira to Present at Upcoming Investor Conferences
4. Hospira Announces FDA Approval of Topotecan Injection
5. Hospira Reports Fourth-Quarter and Full-Year 2010 Results
6. Hospira to Host Conference Call for Fourth-Quarter 2010 Results and 2011 Projections
7. Hospira Launches Piperacillin and Tazobactam for Injection in the United States
8. Hospira Announces New Contracts in Effect with Novation for Infusion Pumps, Solutions and Equipment
9. Hospira to Host Conference Call for Third-Quarter 2010 Results
10. Hospira Receives TGA Approval for Nivestim™, Australias First Biosimilar Filgrastim
11. Hospira Japan Receives Approval for New Indication for Precedex IV™ 200ug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016 Research and ... Plastic Surgery Products Market 2016-2020" report to their ... , The global plastic surgery products market ... during the period 2016-2020. , ,The growing adoption of ... the growth of the market. Lasers are used to ...
(Date:4/28/2016)... April 28, 2016 , Net Sales of ... basis over the prior year period, and an increase of ... , Diluted EPS for the first quarter were $0.52 reported, ... $2.00 adjusted, an increase of 29.9% over the prior year ... adjusted earnings guidance for 2016 Zimmer Biomet Holdings, ...
(Date:4/28/2016)... 2016 TapImmune,Inc. (TPIV), a ... and gene-based immunotherapeutics and vaccines for the treatment of cancer ... the 3rd Annual Growth Capital Expo to be ... at Caesars Palace in Las Vegas, Nevada.  The Company ... 4 th by Dr. John N. Bonfiglio ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... In many parts of the world, ... childhood mortality. This is particularly true in underdeveloped parts of Africa where clean sources ... New England’s campus in Tangier, Morocco, will examine this global health issue and consider ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Infrastructure Management solutions, announces today the availability of its latest software release, ... of capacity management and optimization, providing new analytical capabilities that assess complex ...
(Date:4/28/2016)... ... April 28, 2016 , ... Amada Senior Care, premier provider of non-medical in-home ... – its San Antonio West location. Prior to entering the senior care industry, Amada ... opening of Amada San Antonio West will take place on Friday, April 29th. ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Collaboration Platform™ , today announced a new Residency Education & Collaboration Platform ... medical knowledge, educational resources, and a host of collaboration tools designed to ...
(Date:4/28/2016)... PA (PRWEB) , ... April 28, 2016 , ... ... Browne, M.D. has been named a Top Doc in Physical Medicine and Rehabilitation ... conjunction with Castle Connolly Medical, Ltd. by randomly surveying physicians and medical leadership ...
Breaking Medicine News(10 mins):